Psylutions and the DEA

In August 2025, the psychedelics movement crossed an unprecedented threshold. The U.S. Drug Enforcement Administration (DEA) announced that it would forward a petition to reschedule psilocybin, the psychoactive compound found in “magic mushrooms”, to the Department of Health and Human Services (HHS) for scientific review.

For more than fifty years, psilocybin has been trapped in the confines of Schedule I classification, branded as having no medical use and a high potential for abuse. The DEA’s referral doesn’t end prohibition overnight, but it signals that the agency is finally deferring to science. If HHS recommends rescheduling, psilocybin could move to Schedule II, unlocking medical pathways, clinical trials, and access for patients under programs like Right to Try.

The significance of this move extends far beyond regulatory procedure. A Schedule II designation could give patients in palliative care, as well as veterans struggling with PTSD, a legal route to therapies long known to be promising. For researchers, it would mean fewer barriers to conducting trials and securing funding, accelerating the pace of discovery.

Rhonda DeSantis, founder of Psylutions, sees the decision as more than bureaucratic progress:

“This crucial step reflects a long-overdue alignment between policy and science and brings healing one step closer to those who need it most.”

Based in Denver, Psylutions holds the distinction of being Colorado’s first licensed psilocybin cultivator and manufacturer. From day one, the company has emphasized precision, verification, and effectiveness as the pillars of its work.

That commitment has translated into significant infrastructure investments:

Strain optimization for consistent potency and therapeutic predictability.

Lab-verified dosing, a critical bridge from traditional use to evidence-based medicine.

Triple HEPA filtration systems to mitigate contamination during cultivation.

Already, Psylutions supplies over half of Colorado’s licensed healing centers, providing psilocybin for chronic pain, trauma, end-of-life care, and mental wellness. The company’s partnerships illustrate how a regulated supply chain can ensure patients receive treatments that are safe, consistent, and trusted by clinicians.

DeSantis underscores the stakes:

“As soon as psilocybin is rescheduled, patients facing terminal illness and veterans at risk of suicide will finally have safe, legal access through Right to Try. Psylutions is committed to making sure that access is built on medicine that is effective, rigorously verified, and responsibly produced.”

For Psylutions’ leadership, the DEA’s action is more than incremental progress — it represents a turning point for how society understands psychedelics.

“As agencies begin engaging with medical evidence over stigma, we are entering a watershed moment,” said Henry Baskerville, Psylutions’ general counsel and partner. “I believe psychedelics hold even greater potential for significant medical applications than cannabis, and it is critical we approach this transition with the highest standards of legal integrity and patient safety.”

Unlike cannabis, which often saw commercialization race ahead of validation, psilocybin enters the spotlight during an era of intense scientific scrutiny. This alignment between regulation and evidence could establish a foundation for psychedelics that avoids many of the pitfalls cannabis faced.

The DEA’s action arrives within a larger context of reform:

State initiatives: Colorado and Oregon already operate regulated psilocybin frameworks, with more states considering similar measures.

Federal research momentum: Academic and medical institutions are scaling up clinical studies on psilocybin for depression, anxiety, PTSD, and addiction.

Shifting public opinion: Polling increasingly supports regulated access, especially for treatment-resistant conditions and end-of-life care.

If rescheduling occurs, the immediate ripple effects will be profound: researchers will gain streamlined access to study approvals, clinicians will have new pathways to integrate psilocybin into care, and patients, particularly veterans and those in palliative care, will finally see hope translate into reality.

Psilocybin’s potential move from Schedule I to Schedule II marks more than a legal reclassification. It symbolizes the cultural shift from fear to evidence, from stigma to science.

For Psylutions, that means redoubling efforts to ensure that precision, verification, and patient safety remain the guiding lights of the industry. As Baskerville noted, success will hinge on balancing access with accountability:

“As access grows, safety, transparency, and successful patient outcomes will be paramount.”

The story of psilocybin is far from finished. But with the DEA’s recent decision and companies like Psylutions laying the groundwork, the next chapter in psychedelic medicine is already being written, one that may finally deliver healing to those who need it most.